REPL - IPO Update: Hookipa Pharma Readies $100 Million IPO
Quick Take
Hookipa Pharma (HOOK) has filed proposed terms to raise $100 million in a U.S. IPO, per an amended registration statement.
Hookipa is advancing a pipeline of immunotherapeutics for infectious diseases and cancers.
HOOK has generated promising trial results for its lead candidate, has a multi-program collaboration partnership with Gilead, and the IPO appears reasonably valued.
Company & Technology
New York-based Hookipa was founded in 2011 to develop therapeutics that use the patient’s immune system to induce a powerful killer T cell response for the treatment of infectious diseases and cancer.